Alzheimer's drug Leqembi sales may be slow at first: Analysts

Analysts believe the Medicare registry requirement and new guidance on Leqembi's prescription label could potentially weigh on sales in the near term.

Related Keywords

Michael Yee ,Marc Goodman ,Yatin Suneja ,Paul Matteis ,Jefferie Yee ,National Institute On ,Drug Administration ,National Institute ,Business ,Biotechnology ,Biotech And Pharmaceuticals ,Pharmaceuticals ,Health Care Industry ,Eisai Co Ltd ,Biogen Inc ,Science ,Social Issues ,Alzheimer X27s Disease ,Fda ,Business News ,